Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 19, 2022, PhaseBio Pharmaceuticals, Inc. (the "Company") held its 2022 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2022 (the "Proxy Statement"). Of the 48,690,590 shares outstanding as of the record date, 35,570,975 shares, or 73.06%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of Directors

The Company's stockholders elected the three Class I nominees named in the Proxy Statement to serve as directors until the 2025 annual meeting of stockholders and until their respective successors are elected and qualified, or, if sooner, until the director's death, resignation or removal, by the following votes:



Name                               For           Withheld        Broker Non-Votes
Edmund P. Harrigan              25,066,140       2,634,121          7,870,714
William D. Humphries            27,190,918        509,343           7,870,714
Richard A. van den Broek        25,054,683       2,645,578          7,870,714

Proposal No. 2: Ratification of the selection of KPMG LLP

The Company's stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022, by the following votes:



           For            Against        Abstain        Broker Non-Votes
        33,711,915       1,786,377       72,683                -

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses